NVCR NovoCure Ltd

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Commercialization of TTFields therapy devices (Optune Gio, Lua, Pax) delivering electric fields to kill cancer cells for solid tumor cancers
• • New emphasis on brain metastases from NSCLC with September 2025 Phase 3 METIS trial showing 28% lower risk of intracranial progression; Optune Mya PMA submitted, FDA review ongoing
• • Strategic expansion to pancreatic cancer with 2026 FDA approval of Optune Pax based on PANOVA-3 trial; survival improved to 16.2 vs 14.2 months (p=0.039)
• • Sales force grew to 217 globally as of December 2025; estimated 8,200 GBM, 30,000 NSCLC, 15,000 pancreatic cancer patients in U.S. eligible and seeking treatment in 2026
• • Unusual milestone: simultaneous regulatory progress with multiple devices—PMA filing acceptance for brain metastases (Optune Mya) and first U.S. approval for pancreatic cancer device Optune Pax

Risk Factors

• • FDA PMA approval dependency for Optune Gio sales; majority revenue from newly diagnosed and recurrent GBM indications
• • Geopolitical risk from Greater China market reliance on Zai partnership for development and commercialization
• • Production dependency on third-party manufacturers for sufficient quality and quantity of Products
• • Competition risk from alternative therapies impacting market acceptance despite FDA and CE approvals
• • Historical substantial operating losses with intermittent profits; ongoing high commercialization and R&D expenses

Management Discussion & Analysis

• • Revenue and profitability details not provided in the provided MD&A excerpt
• • No segment performance data disclosed
• • Cash flow, capital allocation, and buybacks or dividends details absent
• • Forward-looking guidance or emerging risks not mentioned in the excerpt

What are the latest NVCR SEC filings in 2026?

NovoCure Ltd (NVCR) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on July 23, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did NVCR file its most recent 10-K annual report?

NovoCure Ltd (NVCR) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view NVCR 10-Q quarterly reports?

NovoCure Ltd (NVCR)'s most recent 10-Q quarterly report was filed on April 30, 2026. SignalX displays every NVCR 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has NVCR filed recently?

NovoCure Ltd (NVCR)'s most recent 8-K was filed on July 23, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find NVCR insider trading activity (Form 4)?

SignalX aggregates every NVCR Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does NVCR file with the SEC?

NovoCure Ltd (NVCR) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new NVCR filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for NovoCure Ltd (NVCR).

What is NVCR's SEC CIK number?

NovoCure Ltd (NVCR)'s SEC CIK (Central Index Key) number is 1645113. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1645113 to look up all NVCR filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find NVCR return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from NovoCure Ltd (NVCR) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.